What is GlaxoSmithKline Pharmaceuticals Ltd. Quarterly Revenue?

GlaxoSmithKline Pharmaceuticals Ltd. Quarterly Revenue GlaxoSmithKline Jun-2026 Quarterly Revenue is Rs 986 Cr which is growth of 16.2% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Quarterly Net Profit?

GlaxoSmithKline Pharmaceuticals Ltd. Quarterly Net Profit GlaxoSmithKline Jun-2026 Quarterly Net Profit is Rs 253 Cr which is growth of 23.8% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Annual Revenue?

GlaxoSmithKline Pharmaceuticals Ltd. Annual Revenue GlaxoSmithKline Mar-2026 Annual Revenue is Rs 3,933 Cr which is growth of 1.7% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Annual Net Profit?

GlaxoSmithKline Pharmaceuticals Ltd. Annual Net Profit GlaxoSmithKline Mar-2026 Annual Net Profit is Rs 1,012 Cr which is growth of 10.1% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Total Shareholders Fund?

GlaxoSmithKline Pharmaceuticals Ltd. Total Shareholders Fund GlaxoSmithKline Mar-2026 Total Shareholders Fund is Rs 2,241 Cr which is growth of 15.0% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Total Assets?

GlaxoSmithKline Pharmaceuticals Ltd. Total Assets GlaxoSmithKline Mar-2026 Total Assets is Rs 4,275 Cr which is growth of 4.2% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Book Value Per Share?

GlaxoSmithKline Pharmaceuticals Ltd. Book Value Per Share GlaxoSmithKline Mar-2026 Book Value Per Share is 132 Rs which is growth of 15.0% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. ROE?

GlaxoSmithKline Pharmaceuticals Ltd. ROE GlaxoSmithKline Mar-2026 ROE is 45% which is growth of 2.0% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Cash From Operating Activity?

GlaxoSmithKline Pharmaceuticals Ltd. Cash From Operating Activity GlaxoSmithKline Mar-2026 Cash From Operating Activity is Rs 881 Cr which is growth of -31.1% YoY.

What is GlaxoSmithKline Pharmaceuticals Ltd. Net Cash Flow?

GlaxoSmithKline Pharmaceuticals Ltd. Net Cash Flow GlaxoSmithKline Mar-2026 Net Cash Flow is Rs 530 Cr which is growth of 11.7% YoY.

GlaxoSmithKline Pharmaceuticals Ltd.

NSE: GLAXO | BSE: 500660

Expensive Performer

Download real time

-29.50(-1.16%)

16,338

NSE+BSE Volume

NSE 14 Oct, 2026 1:46 PM (IST)

Portfolio

Alert

My Notes

GlaxoSmithKline quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for GlaxoSmithKline share price target, revenues, EPS, net income and more

GlaxoSmithKline quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue GlaxoSmithKline Jun-2026 Quarterly Revenue is Rs 986 Cr which is growth of 16.2% YoY.
POSITIVE
Quarterly Net Profit GlaxoSmithKline Jun-2026 Quarterly Net Profit is Rs 253 Cr which is growth of 23.8% YoY.

GlaxoSmithKline Pharmaceuticals Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	986.1	1,024.9	1,054.4	1,004.9	848.6	1,005.5	981.4	1,032.2	846.9	940.7	833.3	981.9	774.8
SR_Q Operating Rev.	924.4	989.2	1,022.6	973.6	804.8	966.1	946.4	1,000.1	811	910.9	805	953.4	738
OI_Q Other Income	61.6	35.7	31.8	31.3	43.8	39.5	35.1	32.2	35.9	29.9	28.3	28.5	36.8
OEXPNS_Q Operating Exp.	631.3	642	655	639	554.1	635.3	656.2	681.1	581.6	655.6	587.5	666.8	596.8
OEXPNS_Q Operating Exp.	631.3	642	655	639	554.1	635.3	656.2	681.1	581.6	655.6	587.5	666.8	596.8
OP_Q Operating Profit	293.2	347.2	367.6	334.7	250.8	330.7	290.2	319	229.4	255.3	217.5	286.6	141.3
OPMPCT_Q Operating Profit Margin %	31.71%	35.10%	35.95%	34.37%	31.16%	34.24%	30.66%	31.89%	28.29%	28.03%	27.02%	30.06%	19.14%
DEP_Q Depr.	15.8	13.2	20.3	17.4	15.5	14.7	18.8	16.9	16.4	18.1	17.1	18.1	16.4
INT_Q Interest	1	0.6	1.2	0.5	0.4	0.6	0.1	0.3	0.4	0.8	0.3	0.4	0.3
PBT_Q Profit Before Tax	338	369.1	377.9	350.7	278.6	354.9	306.4	338.7	248.5	268.7	65.1	296.5	178.7
TAX_Q Tax	84.7	94.2	100.7	95.7	73.9	94.8	77.8	90	66.8	75.6	19.6	81	48.1
NP_Q Net Profit	253.3	274.9	277.2	255	204.7	260.1	228.6	248.7	181.7	193.1	45.5	215.5	130.6
EPS_adj_Q EPS Adj. latest	15	16.2	16.4	15.1	12.1	15.4	13.5	14.7	10.7	11.4	2.7	12.7	7.7
NP_TTM Net profit TTM	1,060.5	1,011.8	997	948.4	942.1	919.1	852	668.9	635.8	584.7	523.1	641.6	619.7
EPS_TTM Basic EPS TTM	62.6	59.7	58.9	56	55.6	54.3	50.3	39.5	37.5	34.5	30.9	37.9	36.6
earnings_transcripts Earnings Transcripts
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

GlaxoSmithKline competitor comparison and performance snapshot within industry

GlaxoSmithKline annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue GlaxoSmithKline Mar-2026 Annual Revenue is Rs 3,933 Cr which is growth of 1.7% YoY.
POSITIVE
Annual Net Profit GlaxoSmithKline Mar-2026 Annual Net Profit is Rs 1,012 Cr which is growth of 10.1% YoY.

GlaxoSmithKline Pharmaceuticals Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
SR_A Total Rev. Ann. ⌄	5.8%	5.3%	4,070.2	3,932.8	3,866.1	3,530.7	3,317.9	3,293.7	3,030.7	3,302.2	3,230	2,925.2	2,975	2,857
TotalOperatingRevenues_A Operating Rev. Ann.	5.6%	5.4%	3,909.8	3,790.2	3,723.5	3,407.3	3,216.3	3,217.5	2,920.5	3,224.7	3,128.5	2,871.7	2,903	2,735.2
OI_A Other Income Ann.	12%	5.3%	160.4	142.6	142.6	123.5	101.5	76.2	110.2	77.6	101.5	53.5	72	121.8
OEXPNS_A Operating Exp. Ann.	1%	1.4%	2,567.2	2,490	2,554.2	2,506.6	2,416.9	2,461.7	2,322.7	2,566.2	2,522.1	2,363.3	2,483.1	2,258.4
OEXPNS_A Operating Exp. Ann.	1%	1.4%	2,567.2	2,490	2,554.2	2,506.6	2,416.9	2,461.7	2,322.7	2,566.2	2,522.1	2,363.3	2,483.1	2,258.4
OP_A Operating Profit Ann.	17.6%	16.8%	1,342.6	1,300.2	1,169.3	900.7	799.4	755.8	597.8	658.5	606.5	508.4	419.9	476.8
OPMPCT_A OPM Ann. %	11.1%	10.9%		33.06%	30.24%	25.51%	24.09%	22.95%	19.72%	19.94%	18.78%	17.38%	14.12%	16.69%
TotalExpenses_A Total Exp. Ann. ⌄	1%	1.3%		2,559.2	2,622.3	2,578.1	2,484.5	2,531.9	2,404.8	2,655.2	2,571.2	2,401.4	2,509.7	2,283.4
OtherExpenses_A Other Exp. Ann.	3.9%	8.3%	601	558.7	607.3	593.8	498.1	462.3	375.2	629.8	631.3	599.1	606.3	587.4
EmployeeBenefitExpenses_A Employee Exp. Ann.	0.7%	-0.3%	613.7	607.3	579.7	624.4	595	610.2	616.2	628.6	537.2	523.4	483	443.4
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	17%	15.3%		1,442.8	1,311.9	1,024.1	900.9	832	708	736	708	562	492	598.6
EBIDTPCT_A EBITDA Ann. margin %	10.6%	9.4%		36.69%	33.93%	29.01%	27.15%	25.26%	23.36%	22.29%	21.92%	19.21%	16.54%	20.95%
INT_A Interest Ann.	14.5%	-5.1%	3.3	2.7	1.3	1.8	1.8	2	3.5	6.3	0.6	0.2	0.3
DEP_A Depr.	0.3%	-3.3%	66.8	66.4	66.8	69.7	65.8	68.2	78.6	82.7	48.6	38	26.4	25
PBT_A PBT Ann.	18.2%	24.9%	1,435.6	1,376.2	1,248.4	809	832.4	773.4	453.2	322.5	663.7	541.6	511.1	575.9
TAX_A Tax Ann.	17%	17%	375.2	364.4	329.4	224.4	227.7	396.9	166.5	212.5	238.4	189.6	174.3	201.4
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	18.7%	28.7%		1,011.8	919.1	584.7	604.7	376.6	286.7	110.1	425.4	352	336.8	374.5
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	18.5%	23.1%	1,060.5	1,011.8	919.1	584.7	607.8	1,690.5	357.6	110.1	425.4	352	336.8	374.5
NETPCT_A NPM Ann. %	12.2%	16.9%		26.69%	24.68%	17.16%	18.89%	52.54%	12.24%	3.41%	13.59%	12.25%	11.60%	13.69%
EPS_adj_A EPS Adj. latest Ann.	18.5%	23.1%		59.7	54.3	34.5	35.9	99.8	21.1	6.5	25.1	20.8	19.9	22.1
result_notes Result Notes				Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

1.7%

2Y CAGR

5.5%

3Y CAGR

5.8%

5Y CAGR

5.3%

7Y CAGR

2.9%

10Y CAGR

3.2%

Total Revenue Annual growth is lower than historical averages.

Net Profit Ann.

1Y CHG

10.1%

2Y CAGR

31.5%

3Y CAGR

18.5%

5Y CAGR

23.1%

7Y CAGR

13.2%

10Y CAGR

10.4%

Net Profit Annual growth is lower than historical averages.

Operating Exp. Ann.

1Y CHG

-2.5%

2Y CAGR

-0.3%

3Y CAGR

5Y CAGR

1.4%

7Y CAGR

-0.2%

10Y CAGR

Operating Expenses Annual Cr is falling faster than historical averages.

GlaxoSmithKline balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund GlaxoSmithKline Mar-2026 Total Shareholders Fund is Rs 2,241 Cr which is growth of 15.0% YoY.
POSITIVE
Total Assets GlaxoSmithKline Mar-2026 Total Assets is Rs 4,275 Cr which is growth of 4.2% YoY.

GlaxoSmithKline Pharmaceuticals Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	8.5%	8.4%	2,241.2	1,949.2	1,784.1	1,753	2,677.6	1,497.1	1,840	2,142.4	2,080	2,028.2	2,204.6
EQCAP_A Equity Share Capital Ann.	0%	0%	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	84.7	84.7	84.7
TotalShareCapital_A Total Share Capital Ann.	0%	0%	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	84.7	84.7	84.7
ReservesAndSurplus_A Reserves Plus Surplus Ann.	9.3%	9.3%	2,071.8	1,779.8	1,623.7	1,585.3	2,508.2	1,327.7	1,670.6	1,973	1,995.3	1,943.5	2,119.9
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	9.3%	9.3%	2,071.8	1,779.8	1,623.7	1,585.3	2,508.2	1,327.7	1,670.6	1,973	1,995.3	1,943.5	2,119.9
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	2.4%	-0.3%	276.6	250.9	252.8	257.7	270.6	280.5	289.4	315.9	289	275.5	291.2
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	-	-
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	61.6%	-5%	17.3	2.5	6.6	4.1	9.7	22.3	28.9	2.2	2.2	3.5	5.7
CL_A Total Current Liabilities Ann. ⌄	10.1%	5.9%	1,757.1	1,900.8	1,510.9	1,317	1,674.4	1,319.4	1,002.1	1,450.9	1,596	717.5	574.9
TradePayables_A Trade Payables Ann.	9.5%	4.2%	549.7	704	613.2	418.6	546.6	448	354.2	403	502.5	275.9	323.1
OtherCurrentLiabilities_A Other Current Liabilities Ann.	17.9%	5.7%	788.3	780.4	504.2	480.7	799.8	596.8	367.2	956	996.4	393.3	206.7
ShortTermProvisions_A ST Provisions Ann.	0.1%	8.8%	419.2	416.4	393.5	417.8	328	274.6	280.7	91.9	97.1	48.3	45.1
TL_A Total Capital Plus Liabilities Ann.	8.7%	6.7%	4,274.9	4,100.9	3,547.8	3,327.7	4,622.6	3,097.1	3,131.5	3,909.2	3,965	3,021.2	3,070.7
FixedAssets_A Fixed Assets Ann. ⌄	-3.6%	-4.7%	313.7	298	335.2	350.3	361.1	400.1	878.2	1,434.3	1,247.5	863.5	477.7
TangibleAssets_A Tangible Assets Ann.	-2.5%	-4.4%	273.5	269.5	296.8	294.8	295	342.2	707	364.5	250.1	252.7	204
IntangibleAssets_A Intangible Assets Ann.	-42.2%	-31.4%	6.6	13.3	23.6	34.1	34.5	43.4	49.6	65.5	72.7
CapitalWorkInProgress_A Capital Work In Progress Ann.	17.5%	20%	32.9	14.3	13.9	20.3	30.5	13.2	120.1	1,002.6	922.9	573.2	267.7
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	-5.3%	-4.6%	731.8	717.4	782	861	951.9	925.8	1,374.7	1,918	1,802	1,371.3	922.9
NonCurrentInvestments_A Non Current Investments Ann.	1.2%	0.7%	25.4	24.5	24.5	24.5	24.5	24.5	24.5	24.6	47.7	47.7	47.7
DeferredTaxAssets_A Deferred Tax Assets Ann.	0.1%	5.6%	133.6	140.6	146	133.2	112.8	101.7	108.9	60.5	103.1	91.3	100.8
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-73.1%	-13.4%		4	11	88.1	204.6		8.2	11.4	14.6	13.3	13.9
OtherNonCurrentAssets_A Other Non Current Assets Ann.	-0.7%	-8.3%	259.2	250.3	265.3	265	248.9	399.5	355	387.3	389.2	355.6	282.9
CA_A Total Current Assets Ann. ⌄	12.8%	10.3%	3,543.1	3,383.6	2,765.8	2,466.7	3,670.7	2,171.3	1,756.8	1,991.2	2,158.1	1,648.2	2,142.1
CurrentInvestments_A Current Investments Ann.	39%	-	1,391	1,118.3	813.2	518.3	365.6
TradeReceivables_A Trade Receivables Ann.	12.4%	4.8%	273.1	292.6	222.1	192.4	205.2	215.6	99.8	120.5	147	170.8	126.6
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	5.6%	3.2%	1,354.8	1,400.9	1,061.2	1,150.7	2,479.1	1,157.7	1,066.4	1,155.3	1,279.7	882.2	1,377.7
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	-	-											55.1
OtherCurrentAssets_A Other Current Assets Ann.	-17.6%	-19.3%	93.9	108.7	155.1	167.6	108.1	274.7	107.5	228.9	236.2	171.3	66.8
TA_A Total Assets Ann.	8.7%	6.7%	4,274.9	4,100.9	3,547.8	3,327.7	4,622.6	3,097.1	3,131.5	3,909.2	3,965	3,021.2	3,070.7
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	15%	2%	545.2	487.6	384	358.5	365.3	493.2	483	573.5	704.9	983	1,315
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	0%	0%	125.4	125.4	125.4	125.4	125.4	125.4	125.4	125.4	40.7	40.7	40.7
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	1.2%	0.7%	25.4	24.5	24.5	24.5	24.5	24.5	24.5	24.6	47.7	47.7	0.1
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

4.2%

2Y CAGR

9.8%

3Y CAGR

8.7%

5Y CAGR

6.7%

7Y CAGR

1.3%

10Y CAGR

3.4%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

-7.6%

2Y CAGR

7.8%

3Y CAGR

10.1%

5Y CAGR

5.9%

7Y CAGR

2.8%

10Y CAGR

11.8%

Total Current Liabilities Annual Cr is falling faster than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

15%

2Y CAGR

12.1%

3Y CAGR

8.5%

5Y CAGR

8.4%

7Y CAGR

0.6%

10Y CAGR

0.2%

Total ShareHolders Funds Annual growth is higher than historical averages.

GlaxoSmithKline ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share GlaxoSmithKline Mar-2026 Book Value Per Share is 132 Rs which is growth of 15.0% YoY.
POSITIVE
ROE GlaxoSmithKline Mar-2026 ROE is 45% which is growth of 2.0% YoY.

GlaxoSmithKline Pharmaceuticals Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
BVSH_A BVSH Ann.	8.5%	8.4%	132.3	115.1	105.3	103.5	158.1	88.4	108.6	126.5	245.6	239.5	260.3
ROA_A RoA Ann. %	9%	15.4%	23.66%	22.41%	16.48%	18.26%	36.57%	11.54%	3.51%	10.88%	8.87%	11.14%	12.19%
ROE_A ROE Ann. %	9.2%	13.6%	45.14%	47.14%	32.77%	34.66%	63.13%	23.88%	5.98%	19.85%	16.92%	16.60%	16.98%
ROCE_A ROCE Ann. %	9.6%	9.1%	54.66%	56.59%	46.85%	41.53%	25.90%	35.40%	30.68%	26.82%	22.11%	20.21%	22.98%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	10.8%	9.4%	38.06%	35.23%	30.05%	28.01%	25.85%	24.24%	22.82%	22.62%	19.56%	16.94%	21.88%
PBITMargin_A EBIT Ann. Margin %	11.8%	11%	36.31%	33.43%	28.01%	25.96%	23.74%	21.54%	20.26%	21.07%	18.24%	16.03%	20.97%
PBTMargin_A PBT Ann. Margin %	11.9%	18.5%	36.31%	33.52%	23.74%	25.88%	24.03%	15.51%	10.00%	21.21%	18.85%	17.60%	21.05%
NETPCT_A NPM Ann. %	12.2%	16.9%	26.69%	24.68%	17.16%	18.89%	52.54%	12.24%	3.41%	13.59%	12.25%	11.60%	13.69%
ASETTO_A Asset Turnover Ann. %	4%	0%	0.9	1	1	0.8	0.8	0.9	0.9	0.8	0.8	1	0.9
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	1.7%	3.3%	2	1.8	1.8	1.9	2.2	1.7	1.8	1.4	1.4	2.3	3.7
QuickRatio_A Quick Ratio Ann.	6.3%	6.7%	1.8	1.5	1.5	1.5	1.9	1.3	1.3	1	1	1.7	2.8
DividendPayoutNP_A Dividend Payout to NP Ann.	-34.6%	-18.1%	0.7	0.8	0.9	2.5	0.3	1.9	3.1	0.7	1.4	2.5	2.8
EarningRetention_A Earning Retention Ann. %	-	-	29.69%	18.90%	7.29%	-150.86%	69.94%	-89.50%	-207.86%	30.31%	27.81%	-25.75%	-41.34%
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	34.02%	24.40%	17.16%	-126.37%	71.11%	-55.35%	-75.79%	37.45%	34.84%	-16.63%	-32.52%
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	34.02%	24.40%	17.16%	-126.37%	71.11%	-55.35%	-75.79%	37.45%	34.84%	-16.63%	-32.52%
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	20.6%	9.9%	37,327.4	47,342.3	31,856.1	21,281.2	25,692.3	23,243.6	20,028.9	20,865.1	16,384.9	22,286.7	30,816.6
EVPerNetSales_A EV Per Net Sales Ann.	14.5%	4.4%	9.9	12.7	9.4	6.6	8	8	6.2	6.7	5.7	7.7	11.3
PBV_A Price To Book Value Adjusted	-7.9%	-7.8%	18.95	25.36	23.8	24.23	15.86	28.37	23.08	19.82	10.21	10.47	9.63
EVPerEBITDA_A EV Per EBITDA Ann.	3.1%	-4.6%	25.9	36.1	31.1	23.6	30.9	32.8	27.2	29.5	29.2	45.3	51.5
MarketCapPerSales_A Market Cap Per Sales Ann.	13.4%	4%	10.2	13.1	9.7	7	8.8	8.4	6.5	7	6.2	8	11.8
RetentionRatios_A Retention Ratio Ann. %	-	-	29.68%	18.89%	7.28%	-150.86%	69.93%	-89.50%	-207.86%	30.30%	27.80%	-25.75%	-41.34%
EYield_A Earnings Yield Ann.	-	-	0	0	0	0	0.1	0	0	0	0	0	0
DEBT_CE_A Total Debt to Total Equity Ann.

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

-4.2%

2Y CAGR

17.4%

3Y CAGR

9.2%

5Y CAGR

13.6%

7Y CAGR

12.5%

10Y CAGR

10.3%

ROE Annual % is falling faster than historical averages.

RoA Ann. %

1Y CHG

5.6%

2Y CAGR

19.8%

3Y CAGR

5Y CAGR

15.4%

7Y CAGR

11.7%

10Y CAGR

6.9%

RoA Annual % is growing slower than historical averages.

Current Ratio Ann.

1Y CHG

11.1%

2Y CAGR

5.4%

3Y CAGR

1.7%

5Y CAGR

3.3%

7Y CAGR

5.2%

10Y CAGR

-6%

Current Ratio Annual growth is higher than historical averages.

GlaxoSmithKline cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity GlaxoSmithKline Mar-2026 Cash From Operating Activity is Rs 881 Cr which is growth of -31.1% YoY.
POSITIVE
Net Cash Flow GlaxoSmithKline Mar-2026 Net Cash Flow is Rs 530 Cr which is growth of 11.7% YoY.

GlaxoSmithKline Pharmaceuticals Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
CFO_A Cash from Operating Act. Ann. ⌄	21.8%	8.2%	881.4	1,280	578.9	487.9	819.8	594.9	491	411.2	474.8	232.3	138.3
PBT_A PBT Ann.	18.2%	24.9%	1,376.2	1,248.4	809	832.4	773.4	453.2	322.5	663.7	541.6	511.1	575.9
INT_A Interest Ann.	14.5%	-5.1%	2.7	1.3	1.8	1.8	2	3.5	6.3	0.6	0.2	0.3
TAX_A Tax Ann.	17%	17%	364.4	329.4	224.4	227.7	396.9	166.5	212.5	238.4	189.6	174.3	201.4
CFI_A Cash from Investing Act. Ann.	-21.8%	-1.1%	385.3	-36.5	15	805.2	-419.7	407.6	-63.1	-154.4	-107	303.1	499.1
CFA_A Cash from Financing Act. Ann.	-	-	-737.1	-769.4	-561.5	-1,544.2	-524.2	-695.6	-427.6	-358.4	-306.6	-510.8	-638.3
NCF_A Net Cash Flow Ann. ⌄	-	11.5%	529.6	474.1	32.4	-251.1	-124.1	306.9	0.3	-101.6	61.1	24.6	-1
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	24.1%	40.5%	536.2	62.2	29.7	280.8	404.9	98	97.8	199.4	138.3	113.7	114.7
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	229.8%	21.4%	1,065.8	536.2	62.2	29.7	280.8	404.9	98	97.8	199.4	138.3	113.7

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

-31.1%

2Y CAGR

23.4%

3Y CAGR

21.8%

5Y CAGR

8.2%

7Y CAGR

11.5%

10Y CAGR

20.3%

Cash from Operating Activity Annual is falling faster than historical averages.

Cash from Investing Act. Ann.

2Y CAGR

406.8%

3Y CAGR

-21.8%

5Y CAGR

-1.1%

10Y CAGR

-2.6%

Cash from Investing Activity Annual growth is higher than historical averages.

GlaxoSmithKline investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

GlaxoSmithKline quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

GlaxoSmithKline - Forecaster

Forecaster Analyst Estimates for GlaxoSmithKline share price target, revenues, EPS, net income and more